|
Intravenous Administration In Combination With Cyclophosphamide - United Kingdom
In May 2008, Oncolytics announced that it had started patient enrollment in a clinical trial in the U.K. using intravenous administration of REOLYSIN® in combination with cyclophosphamide.
The primary objectives of the trial include determining the Minimum Effective Immunomodulatory Dose (MED) of cyclophosphamide to obtain successful immune modulation. Secondary objectives include the safety profile of the combination and gathering any evidence of anti-tumour activity.
See related press releases and documents:
May 9, 2008 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Cyclophosphamide Trial
October 23, 2007 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Cyclophosphamide
|
